Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DE-104 vehicle
- Development stage
- Unknown
- Lead developer
- Santen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
DE-104 vehicle is the inactive placebo formulation used as a comparator in clinical trials for DE-104, a small molecule Rho-kinase (ROCK) inhibitor. Developed jointly by Santen Pharmaceutical and Ube Industries, DE-104 was investigated for the treatment of primary open-angle glaucoma and ocular hypertension. The vehicle formulation contains the same excipients and delivery components as the active DE-104 ophthalmic solution but lacks the active ROCK inhibitor ingredient. It serves as a control to allow for double-masked assessment of the safety and intraocular pressure (IOP)-lowering efficacy of the drug candidate in Phase 2 clinical trials.
Beyond the preview
Go deeper on DE-104 vehicle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DE-104 vehicle.